Chengdu Easton is a pharmaceutical company researching, developing, and manufacturing active ingredients and finished dosage forms.
eastonpharma.cnCrawled Nov 10, 2026
Chengdu Yuandong Biological Pharmaceutical Co., Ltd. received the Sichuan Provincial March 8th Red Banner Collective honor for its stable operational performance, scientific development approach, and outstanding contributions by female employees.
The 2026 Sichuan Private Enterprise R&D Investment Top 100 list includes Chengdu Yuandong Biological Pharmaceutical Co., Ltd., recognizing its sustained high-intensity R&D investment and technological innovation.
Chengdu Yuandong Biological Pharmaceutical Co., Ltd. (stock code: 688513) is a high-tech enterprise specializing in R&D, production, and sales of chemical raw drugs, high-end chemical drugs, and biopharmaceuticals. Founded in 2006 and listed on the Shanghai Stock Exchange’s Sci-Tech Board in 2020, the company prioritizes patient-centric innovation and internationalization.
Chengdu Easton Biopharmaceuticals Co experiences a 3.14% decline in stock value. The drop occurs on a single trading day, reflecting market adjustments for the biopharmaceutical company.
Nov 2026Global Banking & Finance ReviewNews article
Chengdu Easton Biopharmaceuticals reports **CNY 990.45 million in sales and revenue** for the nine months ended September 30, 2026, marking a decline from **CNY 1,019.13 million** in the same period the prior year. The company provides a financial update covering its performance over the first three quarters of 2026. The earnings reflect a sequential reduction in revenue compared to the year-ago period.
Oct 2026MarketScreenerNews article
Chengdu Easton Biopharmaceuticals initiates a clinical trial for its HP-002 tablets through its subsidiary, Shanghai Chaoyang Pharmaceutical. The trial marks the enrollment of the first participant, as reported in a Shanghai Stock Exchange filing. HP-002 represents a potential new pharmaceutical product under development by the company.
Aug 2026MarketScreenerNews article
Easton Pharmaceutical secures NMPA approval for its oxazepam drug, enabling commercialization in China. The company partners exclusively with Nhwa Pharmaceutical to distribute the product, combining Easton’s drug development with Nhwa’s established sales network. Both firms are listed on Chinese stock exchanges.
Jun 2025FLCubeNews article